Analyst Research

Report Title Price
Provider: S&P Capital IQ Quantitative Report
£75.00
Provider: Ford Investor Services, Inc.
£8.00
Provider: Laidlaw & Company
£17.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Isis Pharmaceuticals Inc Publishes Data Demonstrating Antisense Targeting Of ApoC-III Significantly Reduces ApoC-III And Triglycerides


Monday, 1 Apr 2013 

Isis Pharmaceuticals Inc announced publication of new data in journal Circulation Research [doi:10.1161/CIRCRESAHA.111.300367] demonstrating that antisense targeting of apolipoprotein C-III (apoC-III) resulted in reductions in apoC-III and triglycerides, each an independent risk factor for cardiovascular disease. Hypertriglyceridemia is a serious medical condition associated with premature coronary artery disease and an increased risk for pancreatitis. Isis is developing antisense apoC-III inhibitor, ISIS-APOCIIIRx, for the treatment of patients with severe hypertriglyceridemia and plans to report top-line data in the middle of this year. Treatment with an antisense compound targeting apoC-III produced a variety of potential cardio-protective effects including dose-dependent reductions of apoC-III and triglycerides in all models and species, including man. In addition, treatment with an antisense compound targeting apoC-III resulted in enhanced triglyceride clearance from blood following a high-fat meal, reduction of VLDL particles and a slight increase in HDL-C levels. In all models and in the Phase 1 study, antisense inhibition of apoC-III was well tolerated. These data were consistent across multiple preclinical models and species and in a Phase 1 study in healthy volunteers demonstrating that Isis' antisense technology was able to produce predictable and consistent responses among different animal models that translate into corresponding activity in man.